{"id":874266,"date":"2025-08-11T18:05:04","date_gmt":"2025-08-11T22:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/"},"modified":"2025-08-11T18:05:04","modified_gmt":"2025-08-11T22:05:04","slug":"oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/","title":{"rendered":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Aug. 11, 2025<\/span><\/span> \/PRNewswire\/ — Oncolytics Biotech\u00ae<\/sup>\u00a0Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Corporation” or the “Company”), a clinical-stage immunotherapy company developing pelareorep,\u00a0today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on\u00a0Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.<\/p>\n

\n

\n
\n \"Oncolytics
\n <\/a>\n <\/p>\n<\/p><\/div>\n

On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
\n

\n
\n Director<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n For<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n %<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Withheld<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n %<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Patricia Andrews<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,498,328<\/span>\n <\/p>\n<\/td>\n

\n

\n 88.83\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,320,714<\/span>\n <\/p>\n<\/td>\n

\n

\n 11.17\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Deborah M. Brown<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,115,110<\/span>\n <\/p>\n<\/td>\n

\n

\n 85.58\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,703,932<\/span>\n <\/p>\n<\/td>\n

\n

\n 14.42\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Jared\u00a0Kelly<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,830,605<\/span>\n <\/p>\n<\/td>\n

\n

\n 91.64\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 988,437<\/span>\n <\/p>\n<\/td>\n

\n

\n 8.36\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Angela Holtham<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,175,887<\/span>\n <\/p>\n<\/td>\n

\n

\n 86.10\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,643,155<\/span>\n <\/p>\n<\/td>\n

\n

\n 13.90\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n James T. Parsons<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,172,958<\/span>\n <\/p>\n<\/td>\n

\n

\n 86.07\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,646,084<\/span>\n <\/p>\n<\/td>\n

\n

\n 13.93\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Wayne Pisano<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,148,894<\/span>\n <\/p>\n<\/td>\n

\n

\n 85.87\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,670,148<\/span>\n <\/p>\n<\/td>\n

\n

\n 14.13\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Jonathan Rigby<\/span>\n <\/p>\n<\/td>\n

\n

\n 9,508,770<\/span>\n <\/p>\n<\/td>\n

\n

\n 80.45\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 2,310,272<\/span>\n <\/p>\n<\/td>\n

\n

\n 19.55\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Bernd R. Seizinger<\/span>\n <\/p>\n<\/td>\n

\n

\n 10,269,441<\/span>\n <\/p>\n<\/td>\n

\n

\n 86.89\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,549,601<\/span>\n <\/p>\n<\/td>\n

\n

\n 13.11\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

In addition to the election of all nominees listed as directors in the management information circular, dated June 18<\/span>, 2025,\u00a0Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.<\/p>\n

For more details on the matters covered at the annual meeting, please refer to the Corporation’s management information circular available on SEDAR at\u00a0https:\/\/www.sedarplus.ca\/home\/<\/a>. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.<\/p>\n

\n About Oncolytics Biotech Inc.<\/b>\n <\/p>\n

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically “cold”\u00a0tumors “hot”\u00a0through the activation of innate and adaptive immune responses.<\/p>\n

The Company is advancing pelareorep in combination with chemotherapy and\/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit:\u00a0www.oncolyticsbiotech.com<\/a>\u00a0or follow the Company on social media on LinkedIn<\/a>\u00a0and on X @oncolytics<\/a>.<\/p>\n

\n Company Contact <\/b>\n <\/p>\n

\n Jon Patton<\/span>
\n
Director of IR & Communication
jpatton@oncolytics.ca<\/a>\u00a0<\/p>\n

\n Investor Relations for Oncolytics<\/b>\n <\/p>\n

\n Mike Moyer<\/span>
\n
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com<\/a>\u00a0<\/p>\n

\n Media Contact for Oncolytics<\/b>\n <\/p>\n

\n Owen Blaschak<\/span>
\n
LifeSci Communications
oblaschak@lifescicomms.com<\/a>\u00a0<\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/2408622\/5454862\/Oncolytics_Biotech_Inc_Logo.jpg<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-302526856.html<\/a><\/p>\n

SOURCE Oncolytics Biotech\u00ae Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO , Aug. 11, 2025 \/PRNewswire\/ — Oncolytics Biotech\u00ae\u00a0Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Corporation” or the “Company”), a clinical-stage immunotherapy company developing pelareorep,\u00a0today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on\u00a0Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as … <\/p>\n

Continue reading “Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-874266","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Aug. 11, 2025 \/PRNewswire\/ — Oncolytics Biotech\u00ae\u00a0Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Corporation” or the “Company”), a clinical-stage immunotherapy company developing pelareorep,\u00a0today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on\u00a0Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as … Continue reading "Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-11T22:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders\",\"datePublished\":\"2025-08-11T22:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/\"},\"wordCount\":454,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/\",\"name\":\"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"datePublished\":\"2025-08-11T22:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/Oncolytics_Biotech_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/","og_locale":"en_US","og_type":"article","og_title":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Aug. 11, 2025 \/PRNewswire\/ — Oncolytics Biotech\u00ae\u00a0Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Corporation” or the “Company”), a clinical-stage immunotherapy company developing pelareorep,\u00a0today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on\u00a0Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as … Continue reading \"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-11T22:05:04+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders","datePublished":"2025-08-11T22:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/"},"wordCount":454,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/","name":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg","datePublished":"2025-08-11T22:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/Oncolytics_Biotech_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/874266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=874266"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/874266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=874266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=874266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=874266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}